Close
Almac
Achema middle east

Industry Reports

PCI Pharma Services to Acquire Millmount Healthcare

PCI Pharma Services is pleased to announce the acquisition of pharmaceutical and healthcare contract packaging services provider Millmount Healthcare, located near Dublin, Ireland. Millmount has been serving pharmaceutical and healthcare customers for over 20 years with...

A New International Conference On The Best Of Italian Track&Trace Technologies : The Marchesini Group And Sea Vision

On October 18th, the Marchesini Group, alongside SEA Vision - the Group’s longstanding Italian partner for vision systems for pharmaceutical and OEM industries - will be at the International Conference Industry 4.0: Trends in Pharma Manufacturing, Technologies & Packaging....

ABL acquisition extends Ardena’s early-phase offering

Early-phase contract development and manufacturing organisation (CDMO), Ardena, has acquired bioanalytical contract laboratory, Analytical Biochemical Laboratory (ABL). The acquisition of Netherlands-based ABL follows the merging of Pharmavize and Crystallics to form Ardena and broadens the CDMO’s...

Gilead Sciences to Acquire Kite Pharma for $11.9 Billion

Gilead Sciences, Inc. and Kite Pharma, Inc announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. The transaction, which values Kite...

Oxford Genetics Secures £7.5 Million Investment

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery,has announced a £7.5 million investment into its operations in the US and the UK by Mercia Technologies PLC, an existing investor, and Invesco Perpetual....

Mundipharma and CellAct announce new deal for the worldwide development and commercialization of smart chemotherapy CAP7.1

The Mundipharma network of independent associated companies announced that it has acquired from CellAct the worldwide development, commercialization and manufacturing rights to CAP7.1. CAP7.1 is a novel pro-drug of anticancer agent etoposide which is metabolized into...

IFM Therapeutics To Be Acquired by Bristol- Myers Squibb To Strengthen Oncology Pipeline Focus On Innate Immunity

Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »